Tesaglitazar is a dual-target PPARalpha/gamma agonist with an EC50 of 13.4 µM for rat PPARalpha and 3.6 µM for human PPARalpha. Tesaglitazar affects lipid and glucose metabolism by activating PPARalpha and PPARgamma receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain[1][2][3].
Molecular Weight:
408.47
Purity:
99.08
CAS Number:
[251565-85-2]
Formula:
C20H24O7S
Target:
PPAR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted